Drug intelligence / Profile preview

Rociverine

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intramuscular, Intravenous

Overview

Rociverine is an antispasmodic drug used to treat urinary, gastrointestinal, and biliary tract spasms. It acts as an anticholinergic agent, providing smooth muscle relaxation by inhibiting the actions of the parasympathetic nervous system. It is also used in some contexts to help reduce the duration of labor.

Brand names: Rilaten
Other names: RociverinumRociverina

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on Rociverine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rociverine.

Explore the full profile